| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
25,700,000 |
| Market
Cap: |
186.58(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.93 - $7.455 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 20.1 |
| Insider 3/6 Months : 20.7 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Verrica Pharmaceuticals is a dermatology therapeutics company focused on the development and commercialization of treatments for people living with skin diseases. Co.'s primary product candidate, VP-102, is a proprietary drug-device combination of its topical solution of cantharidin, a naturally sourced agent to treat topical dermatological conditions, administered through its single-use precision applicator. Co. is initially developing VP-102 for the treatment of molluscum contagiosum, a highly contagious and primarily pediatric viral skin disease, external genital warts and common warts.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
2,060,199 |
2,260,199 |
8,757,101 |
| Total Buy Value |
$0 |
$12,503,039 |
$13,507,039 |
$27,160,283 |
| Total People Bought |
0 |
1 |
2 |
6 |
| Total Buy Transactions |
0 |
9 |
10 |
18 |
| Total Shares Sold |
0 |
137,181 |
288,608 |
288,608 |
| Total Sell Value |
$0 |
$403,821 |
$1,135,213 |
$1,135,213 |
| Total People Sold |
0 |
5 |
5 |
5 |
| Total Sell Transactions |
0 |
10 |
14 |
14 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  White Ted |
President and CEO |
• • – |
2023-08-24 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
203,789 |
|
- |
|
| Goldenberg Gary |
Chief Medical Officer |
• – – |
2023-08-24 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
95,110 |
|
- |
|
| Bonaccorso Joe |
Chief Commercial Officer |
• – – |
2023-08-24 |
4 |
A |
$0.00 |
$0 |
D/D |
62,500 |
125,238 |
|
- |
|
| Hayes Christopher G. |
Chief Legal Officer |
• – – |
2023-08-24 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
156,925 |
|
- |
|
| Hayes Christopher G. |
Chief Legal Officer |
• – – |
2023-07-24 |
4 |
S |
$4.83 |
$163,201 |
D/D |
(33,789) |
81,925 |
|
23% |
|
| White Ted |
President and CEO |
• • – |
2023-07-24 |
4 |
S |
$4.83 |
$244,770 |
D/D |
(50,677) |
128,789 |
|
23% |
|
| Bonaccorso Joe |
Chief Commercial Officer |
• – – |
2023-07-24 |
4 |
S |
$4.83 |
$184,805 |
D/D |
(38,262) |
62,738 |
|
23% |
|
| Goldenberg Gary |
Chief Medical Officer |
• – – |
2023-07-24 |
4 |
S |
$4.83 |
$138,616 |
D/D |
(28,699) |
70,110 |
|
23% |
|
| Manning Paul B |
Director |
– • • |
2023-07-24 |
4 |
B |
$5.02 |
$1,004,000 |
D/D |
200,000 |
7,851,128 |
3.92 |
-23% |
|
| Hayes Christopher G. |
Chief Legal Officer |
• – – |
2023-07-21 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
115,714 |
|
- |
|
| White Ted |
President and CEO |
• • – |
2023-07-21 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
179,466 |
|
- |
|
| Bonaccorso Joe |
Chief Commercial Officer |
• – – |
2023-07-21 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
101,000 |
|
- |
|
| Goldenberg Gary |
Chief Medical Officer |
• – – |
2023-07-21 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
98,809 |
|
- |
|
| Hayes Christopher G. |
Chief Legal Officer |
• – – |
2022-07-11 |
4 |
B |
$3.40 |
$25,500 |
D/D |
7,500 |
15,714 |
2.74 |
-21% |
|
| White Ted |
President and CEO |
• • – |
2022-07-05 |
4/A |
B |
$2.10 |
$15,750 |
D/D |
7,500 |
29,466 |
2.81 |
- |
|
| Manning Paul B |
Director |
– • • |
2022-07-05 |
4 |
B |
$2.10 |
$9,999,998 |
D/D |
4,761,904 |
13,651,128 |
3.92 |
-6% |
|
| Edelman Joseph |
10% Owner |
– – • |
2022-07-05 |
4 |
B |
$2.10 |
$2,999,999 |
I/I |
1,428,571 |
5,038,983 |
1.5 |
-6% |
|
| Hayes Christopher G. |
Chief Legal Officer |
• – – |
2022-07-05 |
4 |
B |
$2.10 |
$11,999 |
D/D |
5,714 |
8,214 |
2.74 |
-6% |
|
| White Ted |
President and CEO |
• • – |
2022-07-05 |
4 |
B |
$2.10 |
$49,999 |
D/D |
23,809 |
29,466 |
2.81 |
-6% |
|
| Goldenberg Gary |
Chief Medical Officer |
• – – |
2022-07-05 |
4 |
B |
$2.10 |
$49,999 |
D/D |
23,809 |
23,809 |
2.74 |
-6% |
|
| Stalfort Sean |
Director |
– • – |
2022-07-05 |
4 |
B |
$2.10 |
$500,000 |
D/D |
238,095 |
700,205 |
2.39 |
-6% |
|
| Manning Paul B |
Director |
– • • |
2021-12-03 |
4 |
B |
$9.22 |
$184,188 |
D/D |
19,977 |
8,149,394 |
3.92 |
-14% |
|
| Manning Paul B |
Director |
– • • |
2021-12-02 |
4 |
B |
$9.45 |
$283,717 |
D/D |
30,023 |
8,129,417 |
3.92 |
-14% |
|
| White Ted |
President and CEO |
• • – |
2021-06-04 |
4 |
B |
$9.95 |
$39,800 |
D/D |
4,000 |
21,966 |
2.81 |
27% |
|
| Davis A Brian |
Chief Financial Officer |
• – – |
2021-06-04 |
4 |
B |
$9.89 |
$49,450 |
D/D |
5,000 |
12,900 |
2.74 |
27% |
|
246 Records found
|
|
Page 2 of 10 |
|
|
0.50 (7.4%) 
